An Open Label, Single Arm Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded With PA2024 [sipuleucel-T] (APC8015F) for Subjects With Objective Disease Progression and Disease-Related Pain on Protocol D9902 Part B.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2013
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2012 Results presented at the 2012 Genitourinary Cancers Symposium, according to a Dendreon Corporation media release.
- 17 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.